Literature DB >> 12115086

Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients.

Scott D Hanes1, Kutay Demirkan, Elizabeth Tolley, Bradley A Boucher, Martin A Croce, G Christopher Wood, Timothy C Fabian.   

Abstract

Patients with nosocomial pneumonia caused by Stenotrophomonas maltophilia often receive inadequate empiric antibiotic therapy, potentially increasing mortality. Knowledge of the risk factors associated with S. maltophilia pneumonia may better guide the selection of empiric antibiotic therapy. Potential risk factors for S. maltophilia pneumonia were retrospectively analyzed for critically ill trauma patients with late-onset gram-negative pneumonia. The effects of S. maltophilia infection and inadequate empiric antibiotic therapy on patient outcomes were also assessed. By multivariate analysis, S. maltophilia pneumonia was found to be associated with cefepime exposure and tracheostomy in patients with a single pneumonia episode and with higher Injury Severity Score and pulmonary contusion in patients with multiple pneumonia episodes. S. maltophilia pneumonia was associated with increased patient morbidity; only inadequate empiric antibiotic therapy was associated with a higher mortality rate. In critically ill trauma patients with late-onset ventilator-associated pneumonia and these risk factors, empiric antibiotic therapy should include agents active against S. maltophilia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115086     DOI: 10.1086/341022

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  31 in total

1.  Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004.

Authors:  G Aisenberg; K V Rolston; B F Dickey; D P Kontoyiannis; I I Raad; A Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

2.  Defining, treating and preventing hospital acquired pneumonia: European perspective.

Authors:  Antoni Torres; Santiago Ewig; Harmut Lode; Jean Carlet
Journal:  Intensive Care Med       Date:  2008-11-07       Impact factor: 17.440

3.  Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries.

Authors:  Xin Zhang; Rui Wang; Xiuzhen Di; Bin Liu; Youning Liu
Journal:  J Thorac Dis       Date:  2014-02       Impact factor: 2.895

Review 4.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

5.  Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients.

Authors:  B Saugel; K Eschermann; R Hoffmann; A Hapfelmeier; C Schultheiss; V Phillip; F Eyer; K-L Laugwitz; R M Schmid; W Huber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-07       Impact factor: 3.267

Review 6.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

7.  Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study.

Authors:  Stijn Blot; Koenraad Vandewoude; Francis Colardyn
Journal:  Intensive Care Med       Date:  2003-02-08       Impact factor: 17.440

8.  Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia.

Authors:  J I Garcia Paez; F M Tengan; A A Barone; A S Levin; S F Costa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-16       Impact factor: 3.267

Review 9.  An Argument for the Use of Aminoglycosides in the Empiric Treatment of Ventilator-Associated Pneumonia.

Authors:  Addison K May
Journal:  Surg Infect (Larchmt)       Date:  2016-04-01       Impact factor: 2.150

10.  Stenotrophomonas maltophilia infections: Clinical characteristics in a military trauma population.

Authors:  Shane B Patterson; Katrin Mende; Ping Li; Dan Lu; M Leigh Carson; Clinton K Murray; David R Tribble; Dana M Blyth
Journal:  Diagn Microbiol Infect Dis       Date:  2019-11-23       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.